Boneprox expands with new capital

The dental tech company Boneprox is aiming for new markets with the biotechnology company BioGaia as an industrial partner and investor. The new capital injection will go to international expansion and further development of the product portfolio.

BackingMinds invested in Boneprox in October 2019 and the company has since then become a leader in AI-based dental image analysis with, among other things, methods to detect systemic diseases through dental X-rays.

Now the company takes in another 11msek from BioGaia and BackingMinds. BioGaia is a global biotechnology company with a presence in over a hundred countries and will support Boneprox in its international expansion.

Boneprox is an innovative company in a sector that is in great need of innovation and digitalisation. The possibilities are endless and we are very much looking forward to developing new products for the global market together with the Boneprox team, says Sebastian Schröder, EVP Business Development at BioGaia.

We are specializing in image diagnostics where the technical basis consists of machine learning and AI. It is a technology that is becoming increasingly in demand in dentistry. That’s how we started with our first product, where you can detect risk for osteoporosis with the help of a standard dental X-ray. We are very happy that BioGaia wants to team up with us and BackingMinds on our journey beyond Scandinavia’s borders, says Peder Remman CEO and co-founder of Boneprox.

Boneprox was founded in 2013 by Anton Kärrbrink, Peder Remman, Theodor Remman. The company provides digital specialist consultations and AI tools for preventive screening of health conditions and public diseases. Boneprox builds its products in close collaboration with dentists, Sahlgrenska Science Park and Aleap.

BackingMinds is the Venture Capital company that invests in growth companies and verticals that the industry often misses. The company was founded in 2016 by the entrepreneurs Sara Wimmercranz and Susanne Najafi and has companies such as TransferGalaxy, Dynamic Code and TrusTrace in their portfolio.

BioGaia is a Swedish world-leading probiotic company that has been at the forefront of microbiome research for more than 30 years. BioGaia develops, markets and sells probiotic products with documented health benefits. To date, over 200 articles on clinical trials with BioGaia’s probiotic strains have been published. The products are sold by nutrition and pharmaceutical companies in more than 100 countries. The parent company BioGaia AB’s B share is listed on Nasdaq Stockholm, the segment for medium-sized companies.

Läs fler inlägg